You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Rational use of metaraminol can improve pharmaceutical care
  1. Zhang Guozhe1,
  2. Gong Kemin1,
  3. Zhu Fengwei2,
  4. Hongjian Ji3
  1. 1 Department of Chinese Medicine, Jiangsu Vocational College of Medicine, Yancheng, Jiangsu, China
  2. 2 Department of Intensive Care Unit, Yancheng Third People's Hospital, Yancheng, Jiangsu, China
  3. 3 Department of Pharmaceutical Care, Jiangsu Vocational College of Medicine, Yancheng, Jiangsu, China
  1. Correspondence to Dr Hongjian Ji, Department of Pharmaceutical Care, Jiangsu Vocational College of Medicine, Yancheng, Jiangsu, China; hongjianji2006{at}163.com

https://doi.org/10.1136/ejhpharm-2021-003125

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Abdeltawab et al 1 recently published a paper in the European Journal of Hospital Pharmacy which gave an excellent report of the effectiveness of metaraminol in critically ill patients with shock. After comparing the effects of norepinephrine with or without metaraminol, meaningful results were provided. As the authors reported, patients who received norepinephrine together with metaraminol needed a longer time for resolution of shock. As a clinical pharmacist working in the ICU for more than 10 years, I hold the opinion that norepinephrine plays a key role in the treatment of ICU patients with shock.2 The abovementioned finding is important for doctors and …

    View Full Text

    Footnotes

    • Contributors ZG and GK conceived of the study and drafted the manuscript. ZF and JH participated in its design and coordination and helped to draft the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.